MARKET

AEZS

AEZS

Aeterna Zentaris Inc
NASDAQ
1.900
0.000
0.00%
After Hours: 1.900 0 0.00% 17:10 03/04 EST
OPEN
1.960
PREV CLOSE
1.900
HIGH
1.960
LOW
1.852
VOLUME
7.39K
TURNOVER
0
52 WEEK HIGH
3.450
52 WEEK LOW
1.360
MARKET CAP
9.23M
P/E (TTM)
-0.3948
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AEZS last week (0226-0301)?
Weekly Report · 13h ago
ISS Endorses Aeterna Zentaris-Ceapro Merger
TipRanks · 02/27 00:38
Weekly Report: what happened at AEZS last week (0219-0223)?
Weekly Report · 02/26 11:09
Weekly Report: what happened at AEZS last week (0212-0216)?
Weekly Report · 02/19 11:11
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
Aeterna Zentaris Inc. Has issued a Letter to Shareholders ahead of its special meeting of shareholders to approve its merger of equals transaction with Ceapro Inc. The company's shares are trading on the Nasdaq and the TSX.
Barchart · 02/15 16:50
Weekly Report: what happened at AEZS last week (0205-0209)?
Weekly Report · 02/12 11:02
Weekly Report: what happened at AEZS last week (0129-0202)?
Weekly Report · 02/05 11:09
Weekly Report: what happened at AEZS last week (0122-0126)?
Weekly Report · 01/29 10:59
More
About AEZS
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Webull offers AEterna Zentaris Inc. (USA) stock information, including NASDAQ: AEZS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEZS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AEZS stock methods without spending real money on the virtual paper trading platform.